U.S. Markets open in 1 hr 19 mins

Rigel Pharmaceuticals Wins FDA Approval, Potential Clinical Catalysts and Analyst Review

NEW YORK, NY / ACCESSWIRE / June 18, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Rigel Pharmaceuticals, Inc., (RIGL), a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.

The company recently announced that TAVALISSE™ (fostamatinib disodium hexahydrate) is available by prescription for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to previous treatment.

Potential catalysts for Rigel, analysts' review, and target READ MORE

Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/rigel-pharmaceuticals-2/

The FDA's approval of TAVALISSE for chronic ITP represents a huge milestone for Rigel and allows the company to advance its efforts to transition the company into commercialization, so that it may bring this therapy to a patient population in need of treatment options. Also, the recent financing is expected to support company' liquidity for at least next one year.

Pipeline review and full analyst research report READ MORE

Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/rigel-pharmaceuticals-2/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To view our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source